Source:http://linkedlifedata.com/resource/pubmed/id/11091219
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2000-12-13
|
| pubmed:abstractText |
A total of 100 children under the age of 17 years with acquired aplastic anaemia (AA) were initially treated with immunosuppressive therapy (IST) (n = 63) or bone marrow transplantation (BMT) (n = 37) from an HLA-matched family donor. The projected 10-year survival rates were 55 +/- 8% and 97 +/- 3% respectively (P = 0.004). Because the IST group included 11 non-responders who were salvaged by BMT from an HLA-matched unrelated donor, we compared failure-free survival (FFS) between the groups. The probability of FFS at 10 years was 97 +/- 3% for the BMT group, compared with 40 +/- 8% for the IST group (P = 0.0001). Seven patients evolved to myelodysplastic syndrome (MDS) with monosomy 7 and the estimated cumulative incidence of MDS 10 years after diagnosis was 20 +/- 7% in the IST group. We compared the outcome of children treated with IST during the two consecutive periods of 1983-91 (group A, n = 40) and 1991-8 (group B, n = 23) to assess the impact of combined therapy with antithymocyte globulin and cyclosporin. The probability of FFS at 7 years follow-up was the same in the two groups (50 +/- 8% vs. 40 +/- 15%, P = 0.40). We recommend BMT as first-line therapy in paediatric severe AA patients with an HLA-matched family donor. Alternative donor BMT is recommended as salvage therapy in patients who relapse or do not respond to initial IST.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
111
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
321-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11091219-Adolescent,
pubmed-meshheading:11091219-Anemia, Aplastic,
pubmed-meshheading:11091219-Antilymphocyte Serum,
pubmed-meshheading:11091219-Bone Marrow Transplantation,
pubmed-meshheading:11091219-Cell Count,
pubmed-meshheading:11091219-Child,
pubmed-meshheading:11091219-Child, Preschool,
pubmed-meshheading:11091219-Cyclosporine,
pubmed-meshheading:11091219-Disease-Free Survival,
pubmed-meshheading:11091219-Female,
pubmed-meshheading:11091219-Follow-Up Studies,
pubmed-meshheading:11091219-Graft vs Host Disease,
pubmed-meshheading:11091219-Humans,
pubmed-meshheading:11091219-Immunosuppressive Agents,
pubmed-meshheading:11091219-Infant,
pubmed-meshheading:11091219-Male,
pubmed-meshheading:11091219-Retrospective Studies,
pubmed-meshheading:11091219-Statistics, Nonparametric,
pubmed-meshheading:11091219-T-Lymphocytes
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation.
|
| pubmed:affiliation |
Department of Developmental Paediatrics, Nagoya University School of Medicine, Japan. kojimas@med.nagoya-u.ac.jp
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|